Thomas John Dietz Sells 20,000 Shares of Cypherpunk Technologies (NASDAQ:CYPH) Stock

Cypherpunk Technologies (NASDAQ:CYPH) Director Thomas John Dietz sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $1.72, for a total transaction of $34,400.00. Following the completion of the sale, the director owned 132,500 shares of the company’s stock, valued at $227,900. This trade represents a 13.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Cypherpunk Technologies Stock Performance

Cypherpunk Technologies stock opened at $1.71 on Friday. The stock’s 50 day simple moving average is $0.81 and its two-hundred day simple moving average is $0.82. The stock has a market cap of $184.27 million, a price-to-earnings ratio of 3.05 and a beta of 0.09. Cypherpunk Technologies has a fifty-two week low of $0.27 and a fifty-two week high of $3.70.

Cypherpunk Technologies (NASDAQ:CYPH) last announced its earnings results on Wednesday, August 12th. The company reported $0.18 earnings per share (EPS) for the quarter.

Analyst Ratings Changes

CYPH has been the subject of a number of research reports. Weiss Ratings upgraded Cypherpunk Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 17th. Wall Street Zen upgraded shares of Cypherpunk Technologies from a “sell” rating to a “hold” rating in a report on Saturday, July 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $1.60 target price on shares of Cypherpunk Technologies in a research report on Thursday. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $1.60.

Hedge Funds Weigh In On Cypherpunk Technologies

Large investors have recently made changes to their positions in the business. Millennium Management LLC bought a new stake in shares of Cypherpunk Technologies in the 4th quarter worth approximately $37,000. LPL Financial LLC bought a new position in Cypherpunk Technologies during the 4th quarter valued at approximately $38,000. Caitong International Asset Management Co. Ltd bought a new position in Cypherpunk Technologies during the 4th quarter valued at approximately $44,000. Sequoia Financial Advisors LLC purchased a new position in Cypherpunk Technologies during the fourth quarter valued at $56,000. Finally, HighTower Advisors LLC purchased a new position in Cypherpunk Technologies during the fourth quarter valued at $59,000. 30.46% of the stock is currently owned by hedge funds and other institutional investors.

Cypherpunk Technologies Company Profile

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.